Insulin Glargine Trial NCT00391027 Marked Completed

On August 11, 2026, the clinical trial registry ClinicalTrials.gov listed an update to a study involving insulin glargine, marketed as Lantus. The trial, titled "A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®," is registered under identifier NCT00391027. This is a Phase 4 study, meaning it was conducted after the compounds involved received regulatory approval. According to the registry, the trial's status is listed as completed as of the date of this update. The study compared Exubera, an inhaled insulin product, with Lantus, a long-acting insulin glargine formulation. No results, findings, or outcome data are included in this status update. The event data provided does not specify enrollment numbers, endpoints met, or any efficacy or safety conclusions from the trial. Readers should note that a "completed" status indicates the trial has finished its planned course, not that specific results have been published or reviewed. Further details on trial design, outcomes, or subsequent publications would need to be obtained directly from the ClinicalTrials.gov listing or associated peer-reviewed literature. For more background on insulin glargine, including its approved uses and general information, see the compound overview.